Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases

Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases: a Retrospective Single-center Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03717519

Acronym

PLTCRC

Enrollment

196

Registered

2018-10-24

Start date

2018-01-01

Completion date

2018-09-01

Last updated

2023-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Colorectal Carcinoma, Stage IV Colon Cancer

Keywords

platelets, thrombocytosis, prognosis

Brief summary

Colorectal cancer (CRC) is the third most common malignancy worldwide and is often metastatic at diagnosis. Despite progresses in surgical techniques and the introduction of novel chemotherapy regimens, many patients still suffer from a poor prognosis. It is therefore of utmost importance to identify prognostic markers that may improve selection of patients. In recent years several studies demonstrated that preoperative blood tests as platelet count or neuthophil-to-lymphocyte ratio could be prognostic factors in CRC as well as other malignancies. The aim of this study was to evaluate the role of preoperative platelet count (PC) in patients with synchronous colorectal liver metastases.

Interventions

DIAGNOSTIC_TESTMeasurement of platelet count at diagnosis

Blood samples were drawn by expert phlebotomists in vacuum blood tubes containing K2-EDTA (Terumo Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens Healthcare Diagnostics, Tarrytown NY, USA). The local reference range for platelets was 150-400 x 109/L. The same analyser was used throughout the study period, and the quality and reproducibility of test results was validated by data of both internal quality control and external quality assessment

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Colorectal cancer with synchronous liver metastases * Possibility to retrieve pre-operative platelet count * Age of 18 years or older * Availabilty of clinical-pathological data * Minimum follow up of 12 months

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	5 years	correlation between high PC and overall survival

Secondary

Measure	Time frame	Description
Clinic-pathological variables	30 days	correlation between high PC and clinic-pathological variables

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026